MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Cytosorbents Corporation Operating Income 2011-2026 | CTSO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Cytosorbents Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.8 M | -31.9 M | -6.36 M | -9.56 M | -2.63 M | -19 M | -15.6 M | -9.84 M | -11.5 M | -9.3 M | -6.89 M | -4.71 M | -3.49 M | -4.44 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.63 M | -31.9 M | -10.9 M |
Quarterly Operating Income Cytosorbents Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.86 M | -3.62 M | -3.89 M | - | -4.83 M | -3.57 M | -4.66 M | - | -7.35 M | -6.56 M | -7.89 M | - | -9.02 M | -8.36 M | -7.79 M | -9.56 M | -5.41 M | -4.92 M | -2.85 M | -2.63 M | -1.96 M | -3.3 M | -2.48 M | -5.43 M | -5.63 M | -3.63 M | -4.29 M | -5.59 M | -2.71 M | -4.19 M | -3.1 M | -3.81 M | -2.15 M | -2.33 M | -1.56 M | -4.57 M | -2.14 M | -2.69 M | -2.09 M | -2.21 M | -2.15 M | -2.23 M | -2.71 M | -2.89 M | -1.48 M | -1.36 M | -1.15 M | - | -880 K | -1.41 M | -1.42 M | - | -601 K | -1.01 M | -1.07 M | - | -1.23 M | -1.11 M | -1.13 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -601 K | -9.56 M | -3.5 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.21 | -0.43 % | $ 3.45 M |  USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 12.93 | -0.92 % | $ 1.94 B | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 10.53 | 0.77 % | $ 1.42 B | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 9.69 | -13.17 % | $ 274 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.82 | -5.91 % | $ 142 M |  France |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 8.32 | -0.48 % | $ 597 M |  Israel |
 |
Establishment Labs Holdings
ESTA
|
-39 M | $ 65.54 | 0.81 % | $ 1.94 B |  Costa-rica |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 4.06 | -4.92 % | $ 859 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 70.78 | -0.59 % | $ 105 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 37.4 | 0.16 % | $ 1.16 B | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
InMode Ltd.
INMD
|
85.4 M | $ 13.57 | -0.62 % | $ 877 M | Israel |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.33 | - | $ 21.5 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 16.8 | -2.38 % | $ 394 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.44 | -0.05 % | $ 121 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Abbott Laboratories
ABT
|
8.05 B | $ 109.06 | -1.49 % | $ 190 B | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 9.49 | -2.57 % | $ 340 M | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 269.13 | -0.13 % | $ 7.59 B | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.07 | -4.61 % | $ 1.26 M | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 31.04 | -5.22 % | $ 1.43 B | USA |
 |
Align Technology
ALGN
|
608 M | $ 172.05 | -2.31 % | $ 12.9 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 8.93 | -1.92 % | $ 688 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 34.17 | 1.27 % | $ 5.09 K | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
-6.45 M | $ 3.74 | -0.13 % | $ 154 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.39 | -0.46 % | $ 40.1 M | USA |
 |
IRadimed Corporation
IRMD
|
26.1 M | $ 101.34 | -1.42 % | $ 1.29 B | USA |